<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2603245104
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cebatix
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CELECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BATTERJEE PHARMACETICAL FACTORY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cebatix belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAID),<br />and specifically a sub-group known as cyclooxygenase-2 (COX-2) inhibitors. Your body makes<br />prostaglandins that may cause pain and inflammation. In conditions such as rheumatoid arthritis<br />and osteoarthritis your body makes more of these. Cebatix acts by reducing the production of<br />prostaglandins, thereby reducing the pain and inflammation.</p><p>Cebatix is used in adults for the relief of signs and symptoms of rheumatoid arthritis,<br />osteoarthritis and ankylosing spondylitis.</p><p>You should expect your medicine to start working within hours of taking the first dose, but you<br />may not experience a full effect for several days.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You have been prescribed Cebatix by your doctor. The following information will help you get<br />the best results with Cebatix. If you have any further questions, please ask your doctor or<br />pharmacist.</p><p>Do not take Cebatix<br />Tell your doctor if any of the following are true for you as patients with these conditions should not take Cebatix.<br />&bull; if you are allergic to celecoxib or any of the other ingredients of this medicine (listed in section 6)<br />&bull; if you have had an allergic reaction to a group of medicines called &ldquo;sulfonamides&rdquo; (e.g., some<br />antibiotics used to treat infections)<br />&bull; if you currently have an ulcer in your stomach or intestines, or bleeding in your stomach or<br />intestines<br />&bull; if as a result of taking acetylsalicylic acid or any other anti-inflammatory and pain-relieving<br />medicine (NSAID) you have had asthma, nose polyps, severe nose congestion, or an allergic<br />reaction such as an itchy skin rash, swelling of the face, lips, tongue or throat, breathing<br />difficulties or wheezing<br />&bull; if you are pregnant. If you can become pregnant during ongoing treatment you should discuss<br />methods of contraception with your doctor<br />&bull; if you are breast-feeding<br />&bull; if you have severe liver disease<br />&bull; if you have severe kidney disease<br />&bull; if you have an inflammatory disease of the intestines such as ulcerative colitis or Crohn&rsquo;s disease<br />&bull; if you have heart failure, established ischaemic heart disease, or cerebrovascular disease, e.g. you<br />have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary<br />reduction of blood flow to the brain; also known as &ldquo;mini-stroke&rdquo;), angina, or blockages of blood<br />vessels to the heart or brain<br />&bull; if you have or have had problems with your blood circulation (peripheral arterial disease) or if<br />you have had surgery on the arteries of your legs</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Cebatix:<br />&bull; if you have previously had an ulcer or bleeding in your stomach or intestines. (Do not take<br />Cebatix if you currently have an ulcer or bleeding in your stomach or intestine)<br />&bull; if you are taking acetylsalicylic acid (even at low dose for heart protective purposes)<br />&bull; if you are taking antiplatelet therapies<br />&bull; if you use medicines to reduce blood clotting (e.g. warfarin/warfarin like anticoagulants or novel<br />oral anti-clotting medicines, e.g. apixaban)<br />&bull; if you use medicines called corticosteroids (e.g. prednisone)<br />&bull; if you are using Cebatix at the same time as other non-acetylsalicylic NSAIDs such as ibuprofen<br />or diclofenac. The use of these medicines together should be avoided<br />&bull; if you smoke, have diabetes, raised blood pressure or raised cholesterol<br />&bull; if your heart, liver or kidneys are not working well your doctor may want to keep a regular check<br />on you<br />&bull; if you have fluid retention (such as swollen ankles and feet)<br />&bull; if you are dehydrated, for instance due to sickness, diarrhoea or the use of diuretics (used to treat<br />excess fluid in the body)<br />&bull; if you have had a serious allergic reaction or a serious skin reaction to any medicines<br />&bull; if you feel ill due to an infection or think you have an infection, as Cebatix may mask a fever or<br />other signs of infection and inflammation<br />&bull; if you are over 65 years of age your doctor will want to monitor you regularly<br />&bull; the consumption of alcohol and NSAIDs may increase the risk of gastrointestinal problems.</p><p>As with other NSAIDs (e.g., ibuprofen or diclofenac) this medicine may lead to an increase in<br />blood pressure, and so your doctor may ask to monitor your blood pressure on a regular basis.<br />Some cases of severe liver reactions, including severe liver inflammation, liver damage, liver<br />failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib.<br />Of the cases that reported time to onset, most severe liver reactions occurred within one month of<br />start of treatment.</p><p>Cebatix may make it more difficult to become pregnant. You should inform your doctor if you are<br />planning to become pregnant or if you have problems to become pregnant (see section on Pregnancy<br />and breast-feeding).</p><p><strong>Other medicines and Cebatix</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines:<br />&bull; Dextromethorphan (used to treat coughs)<br />&bull; ACE inhibitors, angiotensin II antagonists, beta blockers and diuretics (used for high blood<br />pressure and heart failure)<br />&bull; Fluconazole and rifampicin (used to treat fungal and bacterial infections)<br />&bull; Warfarin or other warfarin like medicines (&ldquo;blood-thinning&rdquo; agents that reduce blood clotting)<br />including newer medicines like apixaban<br />&bull; Lithium (used to treat some types of depression)<br />&bull; Other medicines to treat depression, sleep disorders, high blood pressure or an irregular heartbeat<br />&bull; Neuroleptics (used to treat some mental disorders)<br />&bull; Methotrexate (used to treat rheumatoid arthritis, psoriasis and leukaemia)<br />&bull; Carbamazepine (used to treat epilepsy/seizures and some forms of pain or depression)<br />&bull; Barbiturates (used to treat epilepsy/seizures and some sleep disorders)<br />&bull; Ciclosporin and tacrolimus (used for immune system suppression e.g. after transplants)</p><p>Cebatix can be taken with low dose acetylsalicylic acid (75 mg or less daily). Ask your doctor for<br />advice before taking both medicines together.</p><p><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby,<br />ask your doctor or pharmacist for advice before taking this medicine.</p><p><u>Pregnancy</u><br />Cebatix must not be used by women who are pregnant or can become pregnant (i.e. women of<br />child bearing potential who are not using adequate contraception) during ongoing treatment. If you<br />become pregnant during treatment with Cebatix you should discontinue the treatment and contact<br />your doctor for alternative treatment.</p><p><u>Breast-feeding</u><br />Cebatix must not be used during breast-feeding.</p><p><u>Fertility</u><br />NSAIDs, including Cebatix, may make it more difficult to become pregnant. You should tell your<br />doctor if you are planning to become pregnant or if you have problems becoming pregnant.</p><p><u>Driving and using machines</u><br />You should be aware of how you react to Cebatix before you drive or operate machinery. If you<br />feel dizzy or drowsy after taking Cebatix, do not drive or operate machinery until these effects<br />wear off.</p><p><strong>Cebatix contains lactose</strong><br />Cebatix contains lactose (a type of sugar). If you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor before taking this medicinal product.<br />Cebatix contains sodium<br />This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially<br />&lsquo;sodium-free&rsquo;.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your<br />doctor or pharmacist if you are not sure. If you think or feel that the effect of Cebatix is too strong<br />or too weak, talk to your doctor or pharmacist.<br />Your doctor will tell you what dose you should take. As the risk of side effects associated with<br />heart problems may increase with dose and duration of use, it is important that you use the lowest<br />dose that controls your pain and you should not take Cebatix for longer than necessary to control<br />symptoms.</p><p><u>Method of administration</u><br />Cebatix is for oral use. The capsules can be taken at any time of the day, with or without food.<br />However, try to take each dose of Cebatix at the same time each day.<br />If you have difficulty swallowing capsules: The entire capsule contents can be sprinkled onto a<br />level teaspoon of semi-solid food (such as cool or room temperature applesauce, rice gruel, yogurt<br />or mashed banana) and swallowed immediately with a drink approximately 240 ml of water.<br />To open the capsule, hold upright to contain the granules at the bottom then gently squeeze the top<br />and twist to remove, taking care not to spill the contents. Do not chew or crush the granules.</p><p>Contact your doctor within two weeks of starting treatment if you do not experience any benefit.<br />The recommended dose is<br />For osteoarthritis the recommended dose is 200 mg each day, increased by your doctor to a<br />maximum of 400 mg, if needed.</p><p>The dose is usually:<br />◼ one 200 mg capsule once a day; or<br />◼ one 100 mg capsule twice a day.<br />For rheumatoid arthritis the recommended dose is 200 mg each day, increased by your doctor to<br />a maximum of 400 mg, if needed.<br />The dose is usually:<br />◼ one 100 mg capsule twice a day.<br />For ankylosing spondylitis, the recommended dose is 200 mg each day, increased by your doctor<br />to a maximum of 400 mg, if needed.<br />The dose is usually:<br />◼ one 200 mg capsule once a day; or<br />◼ one 100 mg capsule twice a day.</p><p>Kidney or liver problems: make sure your doctor knows if you have liver or kidney problems as<br />you may need a lower dose.</p><p>The elderly, especially those with a weight less than 50 kg: if you are over 65 years of age and<br />especially if you weigh less than 50 kg, your doctor may want to monitor you more closely.<br />You should not take more than 400 mg per day.</p><p><u>Use in children</u></p><p>Cebatix is for adults only, it is not for use in children.<br />If you take more Cebatix than you should<br />You should not take more capsules than your doctor tells you to. If you take too many capsules<br />contact your doctor, pharmacist or hospital and take your medicine with you.<br />If you forget to take Cebatix<br />If you forget to take a capsule, take it as soon as you remember. Do not take a double dose to make<br />up for a forgotten dose.<br />If you stop taking Cebatix</p><p>Suddenly stopping your treatment with Cebatix may lead to your symptoms getting worse. Do not<br />stop taking Cebatix unless your doctor tells you to. Your doctor may tell you to reduce the dose<br />over a few days before stopping completely.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The side effects listed below were observed in arthritis patients who took Cebatix. Side<br />effects marked with an asterisk (*) are listed below at the higher frequencies that occurred in<br />patients who took Cebatix to prevent colon polyps. Patients in these studies took Cebatix at<br />high doses and for a long duration.</p><p>If any of the following happen, stop taking Cebatix and tell your doctor immediately:<br />If you have:<br />- an allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing<br />- heart problems such as pain in the chest<br />- severe stomach pain or any sign of bleeding in the stomach or intestines, such as passing black or<br />bloodstained stools, or vomiting blood<br />- a skin reaction such as rash, blistering or peeling of the skin<br />- liver failure (symptoms may include nausea (feeling sick), diarrhoea, jaundice (your skin or the<br />whites of your eyes look yellow)).</p><p>Very common: may affect more than 1 in 10 people<br />&bull; High blood pressure, including worsening of existing high blood pressure *</p><p>Common: may affect up to 1 in 10 people<br />&bull; Heart attack*<br />&bull; Fluid build-up with swollen ankles, legs and/or hands<br />&bull; Urinary infections<br />&bull; Shortness of breath*, sinusitis (sinus inflammation, sinus infection, blocked or painful sinuses),<br />blocked or runny nose, sore throat, coughs, colds, flu-like symptoms<br />&bull; Dizziness, difficulty sleeping<br />&bull; Vomiting*, stomach ache, diarrhoea, indigestion, wind<br />&bull; Rash, itching<br />&bull; Muscle stiffness<br />&bull; Difficulty swallowing*<br />&bull; Headache<br />&bull; Nausea (feeling sick)<br />&bull; Painful joints<br />&bull; Worsening of existing allergies<br />&bull; Accidental injury</p><p>Uncommon: may affect up to 1 in 100 people<br />&bull; Stroke*<br />&bull; Heart failure, palpitations (awareness of heart beat), fast heart rate<br />&bull; Abnormalities in liver-related blood tests<br />&bull; Abnormalities in kidney-related blood tests<br />&bull; Anaemia (changes in red blood cells that can cause fatigue and breathlessness)<br />&bull; Anxiety, depression, tiredness, drowsiness, tingling sensations (pins and needles)<br />&bull; High levels of potassium in blood test results (can cause nausea (feeling sick), fatigue, muscle<br />weakness or palpitations)<br />&bull; Impaired or blurred vision, ringing in the ears, mouth pain and sores, difficulty hearing*<br />&bull; Constipation, burping, stomach inflammation (indigestion, stomach ache or vomiting), worsening<br />of inflammation of the stomach or intestine<br />&bull; Leg cramps<br />&bull; Raised itchy rash (hives)<br />&bull; Eye inflammation<br />&bull; Difficulty breathing<br />&bull; Skin discolouration (bruising)<br />&bull; Chest pain (generalised pain not related to the heart)<br />&bull; Face swelling</p><p>Rare: may affect up to 1 in 1,000 people<br />&bull; Ulcers (bleeding) in the stomach, gullet or intestines; or rupture of the intestine (can cause<br />stomach ache, fever, nausea, vomiting, intestinal blockage), dark or black stools, inflammation of<br />the pancreas (can lead to stomach pain), inflammation of the gullet (oesophagus)<br />&bull; Low levels of sodium in the blood (a condition known as hyponatraemia)<br />&bull; Reduced number of white blood cells (which help to protect the body from infection) or blood<br />platelets (increased chance of bleeding or bruising)<br />&bull; Difficulty coordinating muscular movements<br />&bull; Feeling confused, changes in the way things taste<br />&bull; Increased sensitivity to light<br />&bull; Loss of hair<br />&bull; Hallucinations<br />&bull; Bleeding in the eye<br />&bull; Acute reaction that may lead to lung inflammation<br />&bull; Irregular heartbeat<br />&bull; Flushing<br />&bull; Blood clot in the blood vessels in the lungs. Symptoms may include sudden breathlessness, sharp<br />pains when you breathe or collapse<br />&bull; Bleeding of the stomach or intestines (can lead to bloody stools or vomiting), inflammation of the<br />intestine or colon<br />&bull; Severe liver inflammation (hepatitis). Symptoms may include nausea (feeling sick), diarrhoea,<br />jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily,<br />itching or chills<br />&bull; Acute kidney failure<br />&bull; Menstrual disturbances<br />&bull; Swelling of the face, lips, mouth, tongue or throat, or difficulty swallowing<br />Very rare: may affect up to 1 in 10,000 people<br />&bull; Serious allergic reactions (including potentially fatal anaphylactic shock)<br />&bull; Serious skin conditions such as Stevens-Johnson syndrome, exfoliative dermatitis and toxic<br />epidermal necrolysis (can cause rash, blistering or peeling of the skin) and acute generalised<br />exanthematous pustulosis (symptoms include the skin becoming red with swollen areas covered<br />in numerous small pustules)<br />&bull; A delayed allergic reaction with possible symptoms such as rash, swelling of the face, fever,<br />swollen glands, and abnormal test results (e.g., liver, blood cell (eosinophilia, a type of raised<br />white blood cell count))<br />&bull; Bleeding within the brain causing death<br />&bull; Meningitis (inflammation of the membrane around the brain and spinal cord)<br />&bull; Liver failure, liver damage and severe liver inflammation (fulminant hepatitis) (sometimes fatal or<br />requiring liver transplant). Symptoms may include nausea (feeling sick), diarrhoea, jaundice<br />(yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or<br />chills<br />&bull; Liver problems (such as cholestasis and cholestatic hepatitis, which may be accompanied by<br />symptoms such as discoloured stools, nausea and yellowing of the skin or eyes)<br />&bull; Inflammation of the kidneys and other kidney problems (such as nephrotic syndrome and minimal<br />change disease, which may be accompanied by symptoms such as water retention (oedema),<br />foamy urine, fatigue and a loss of appetite)<br />&bull; Worsening of epilepsy (possible more frequent and/or severe seizures)<br />&bull; Blockage of an artery or vein in the eye leading to partial or complete loss of vision<br />&bull; Inflamed blood vessels (can cause fever, aches, purple blotches on the skin)<br />&bull; A reduction in the number of red and white blood cells and platelets (may cause tiredness, easy<br />bruising, frequent nose bleeds and increased risk of infections)<br />&bull; Muscle pain and weakness<br />&bull; Impaired sense of smell<br />&bull; Loss of taste</p><p>Not known: frequency cannot be estimated from the available data<br />&bull; Decreased fertility in females, which is usually reversible on discontinuation of the medicine<br />In clinical studies not associated with arthritis or other arthritic conditions, where Cebatix<br />was taken at doses of 400 mg per day for up to 3 years, the following additional side effects<br />have been observed:<br />Common: may affect up to 1 in 10 people<br />&bull; Heart problems: angina (chest pain)<br />&bull; Stomach problems: irritable bowel syndrome (can include stomach ache, diarrhoea, indigestion,<br />wind)<br />&bull; Kidney stones (which may lead to stomach or back pain, blood in urine), difficulty passing urine<br />&bull; Weight gain<br />Uncommon: may affect up to 1 in 100 people<br />&bull; Deep vein thrombosis (blood clot usually in the leg, which may cause pain, swelling or redness of<br />the calf or breathing problems)<br />&bull; Stomach problems: stomach infection (which can cause irritation and ulcers of the stomach and<br />intestines)<br />&bull; Lower limb fracture<br />&bull; Shingles, skin infection, eczema (dry itchy rash), pneumonia (chest infection (possible cough,<br />fever, difficulty breathing))<br />&bull; Floaters in the eye causing blurred or impaired vision, vertigo due to inner ear troubles, sore,<br />inflamed or bleeding gums, mouth sores<br />&bull; Excessive urination at night, bleeding from piles/ haemorrhoids, frequent bowel movements<br />&bull; Fatty lumps in skin or elsewhere, ganglion cyst (harmless swellings on or around joints and<br />tendons in the hand or foot), difficulty speaking, abnormal or very heavy bleeding from the<br />vagina, breast pain<br />&bull; High levels of sodium in blood test results</p><p><strong>Reporting of side effects</strong><br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.</p><p>To report any side effect(s):</p><p><strong>&bull; Saudi Arabia:</strong><br />The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</p><p><strong>&bull; United Arab Emirates</strong></p><p>Pharmacovigilance &amp; Medical Device section<br />- P.O.Box: 1853<br />- Tel: 80011111<br />- Email : pv@mohap.gov.ae<br />- Drug Department Ministry of Health &amp; Prevention, Dubai, UAE<br />&nbsp;</p><p><br /><strong>&bull; Other GCC States:</strong><br />Please contact the relevant competent authority.<br />Council of Arab Health Ministers<br />This is a Medicament<br />- Medicament is a product which affects your health and its consumption contrary to<br />instructions is dangerous for you.<br />- Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the<br />pharmacist who sold the medicament.<br />- The doctor and the pharmacist are the experts in medicines, their benefits and risks.<br />- Do not by yourself interrupt the period of treatment prescribed for you.<br />- Do not repeat the same prescription without consulting your doctor.<br />- Keep all medicaments out of reach of children.<br />Council of Arab Health Ministers<br />Union of Arab Pharmacists<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton box after the<br />word &ldquo;EXP&rdquo;.<br />Do not store above 30&deg;C.<br />To be used within 3 months from the first opening<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how<br />to throw away medicines you no longer use. These measures will help protect the environment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Cebatix contains<br />- The active substance is celecoxib. Each Hard Gelatin capsule contains 200 mg celecoxib.<br />- The other ingredients are Lactose monohydrate, sodium lauryl sulphate, povidone K-30,<br />croscarmellose sodium, magnesium stearate and the Capsule shell.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cebatix is hard gelatin capsules with yellow cap and white body containing white to off white
granular powder.
Cebatix Capsules are available in a pack size of 30 hard gelatin capsules
Cebatix capsules are provided in a white opaque HDPE bottle containing 30 units of Cebatix 200 mg
capsule, packed into a carton box with insert leaflet
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Batterjee pharmaceutical Factory (BATTERJEE PHARMA)<br />Plot E2, Phase 4, Industrial City, Jeddah, Saudi Arabia<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي سيباتكس إلى مجموعة من الأدوية المعروفة بمضادات الالتهاب اللاستيرويدية، وخاصة المجموعة الفرعية المعروفة<br />بمثبطات كوكس- .2يفرز الجسم مادة البروستاجلاندين التي قد تتسبب في حدوث الألم والالتهاب. وفي بعض الحالات مثل التهاب<br />المفاصل الروماتويدي والتهاب المفاصل العظمي يفرز الجسم المزيد من هذه المادة. يعمل السيباتكس على الحد من إفراز<br />البروستاجلاندين، وبالتالي يقلل حدوث الألم والالتهاب<br />ي</p><p>سُتخدم دواء سيباتكس لتخفيف أعراض التهاب المفاصل الروماتويدي والتهاب المفاصل العظمي والتهاب الفقار التصلبي.<br />من المتوقع أن يبدأ تأثير الدواء في خلال ساعات من تناول الجرعة الأولى. ولكن قد لا تشعر بالفاعلية الكاملة للدواء إلا بعد عدة أيام<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>وصف لك الطبيب دواء سيباتكس. ستساعدك المعلومات التالية في الحصول على أفضل النتائج عند العلاج بسيباتكس. إذا كان<br />لديك أي أسئلة أخرى، يُرجى استشارة الطبيب أو الصيدلي.</p><p>لا تتناول سيباتكس<br />أخبر الطبيب إذا كانت أي من الحالات التالية تنطبق عليك حيث أنه يجب على المرضى المصابين بالحالات التالية عدم تناول<br />سيباتكس:<br />- إذا كنت تعاني من الحساسية للسيليكوكسيب أو أي من مكونات الدواء (المدرجة في القسم 6<br />- إذا كنت تعاني من أحد تفاعلات الحساسية لمجموعة من العقاقير المعروفة &quot;بعقاقير السلفوناميد&quot; (مثل بعض المضادات الحيوية<br />ال ُمستخدمة لعلاج الأمراض ال ُمعدية.<br />- إذا كنت تعاني حاليا من قرحة أو نزيف بالمعدة أو الأمعاء.<br />- إذا كان تناول حمض الأسيتيل ساليسيليك أو أي عقار آخر من مسكنات الألم ومضادات الالتهاب اللاستيرويدية، قد ينتج عنه<br />إصابتك بالربو، أو أورام حميدة في الأنف، أو احتقان حاد بالأنف، أو حدوث أحد تفاعلات الحساسية مثل الطفح الجلدي<br />المصحوب بحكة أو تورم الوجه أو الشفتين أو اللسان أو الحلق، أو صعوبة التنفس أو صفير.<br />- إذا كن ِت حاملا. إذا كان هناك احتمال حدوث حمل خلال فترة علاجك بهذا الدواء، فلا بد من مناقشة وسائل منع الحمل المناسبة<br />مع الطبيب<br />- إذا كن ِت في فترة الإرضاع.<br />- إذا كنت تعاني من مرض شديد في الكبد.<br />- إذا كنت تعاني من مرض شديد في الكلى.</p><table><tbody><tr><td>- إذا كنت مصابا</td><td>.</td></tr><tr><td>- إذا كنت تعاني من فشل في القلب أو قصور الشريان التاجي أو الأمراض الدماغية الوعائية مثل ان يتم تشخيص حالتك بأنها</td></tr></tbody></table><p>بالتهاب في الأمعاء مثل التهاب القولون التقرحي أو داء كرونإصابة بنوبة قلبية أو سكتة دماغية أو قصور مؤقت بالشرايين (نقص مؤقت في تدفق الدم إلى المخ؛ ويُعرف أيضا باسم &quot;السكتة<br />الدماغية البسيطة&quot;،) أو ذبحة صدرية أو انسداد في الأوعية الدموية الواصلة إلى القلب أو المخ.<br />- إذا كنت تعاني حاليا أو عانيت مسبقا من مشاكل في الدورة الدموية (أمراض الشرايين الطرفية) أو أجريت عملية جراحية في<br />شرايين الساق.<br />التحذيرات والاحتياطات<br />تحدث إلى الطبيب أو الصيدلي قبل تناول سيباتكس:<br />- إذا كنت قد أ ُصبت ُمسبق ا بقرحة أو نزيف في المعدة أو الأمعاء.<br />(لا تتناول سيباتكس إذا كنت مصابا حاليا بقرحة أو نزيف في المعدة أو الأمعاء)<br />- إذا كنت تتناول حمض الأسيتيل ساليسيليك (حتى وإن كانت جرعة صغيرة لأغراض الوقاية من أمراض القلب).<br />- إذا كنت تستخدم أدوية مضادة لتجلط الدم (مثل وارفارين أو أدوية أخرى مضادة للتجلط يتم تناولها عن طريق الفم مثل ابيكسبان).<br />- إذا كنت تستخدم أدوية تسمى الأدوية الاستيرويدية مثل (بريدنيزون).<br />- إذا كنت تستخدم سيباتكس مع مضادات الالتهاب اللاستيرويدية الخالية من حمض الأسيتيل ساليسيليك مثل آيبوبروفين أو<br />ديكلوفيناك. لا بد من تجنب تناول هذه الأدوية معا في وقت واحد.<br />- إذا كنت من المدخنين أو كنت مصابا بداء السكري أو ارتفاع ضغط الدم أو ارتفاع نسبة الكوليسترول.</p><table><tbody><tr><td>- إذا كان هناك خلل في وظائف القلب أو الكبد أو الكلى، فقد</td><td>يرغب الطبيب في إجراء فحص دوري لك.</td></tr><tr><td>- إذا كنت مصابا باحتباس السوائل في الجسم (مثل تورم الكاحلين والقدمين).</td></tr></tbody></table><p>- إذا كنت مصابا بالجفاف، على سبيل المثال نتيجة لمرض ما أو الاسهال أو استخدام مدرات البول (لعلاج السوائل الزائدة في<br />الجسم.)<br />- إذا كنت قد أ ُصبت بحساسية شديدة أو تفاعل شديد بالجلد لأي دواء.<br />- إذا كنت تشعر بالإعياء نتيجة لعدوى أو تعتقد بأنك مصاب بعدوى، حيث يمكن لدواء سيباتكس إخفاء أعراض الحمى أو</p><p>الأعراض الأخرى للعدوى أو الالتهاب.<br />- إذا كان عمرك يزيد عن 65عاما، فقد يرغب الطبيب في إجراء فحص دوري لك.<br />- استخدام الكحوليات مع مضادات الالتهاب اللاستيرويدية يزيد من خطر الإصابة بمشاكل المعدة والأمعاء.<br />كباقي مضادات الالتهاب اللاستيرويدية الأخرى (مثل آيبوبروفين أو ديكلوفيناك)، قد يؤدي هذا الدواء إلى ارتفاع ضغط الدم، لذلك<br />قد يطلب منك الطبيب متابعة ضغط الدم بانتظام.<br />أوردت التقارير حدوث بعض حالات التفاعلات الشديدة بالكبد، وتشمل التهاب الكبد الشديد وتضرر الكبد وفشل الكبد (والتي يؤدي<br />بعضها إلى نتائج مميتة أو يتطلب زرع كبد) عند العلاج بعقار سيليكوكسيب. من بين تلك الحالات التي أوردتها التقارير، حدثت<br />معظم التفاعلات الشديدة بالكبد خلال شهر واحد من بدء العلاج.<br />قد يؤدي سيباتكس إلى زيادة صعوبة حدوث الحمل. يجب علي ِك إخطار الطبيب إذا كنت تخططين لحدوث حمل أو إذا كانت<br />تواجهين مشاكل تحول دون حدوث الحمل (انظري القسم الخاص بالحمل والرضاعة).<br />التداخلات الدوائية من تناول سيباتكس مع أي أدوية الأخرى<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى:<br />- دكستروميثورفان (لعلاج السعال).<br />- مثبطات الإنزيم المحول للانجيوتنسين أو مضادات مستقبلات الأنجيوتنسين الثاني وحاصرات بيتا ومدرات البول (لعلاج ضغط<br />الدم المرتفع وفشل القلب).<br />- فلوكونازول وريفامبيسين (لعلاج العدوى الفطرية والبكتيرية).<br />- الوارفارين أو مضادات التجلط الفموية الأخرى. (عوامل &quot;ترقق الدم&quot; التي تمنع التجلط وتشمل الأدوية الجديدة مثل ابيكسبان)<br />- الليثيوم (لعلاج بعض أنواع الاكتئاب).<br />- الأدوية الأخرى المتخصصة في علاج الاكتئاب أو اضطرابات النوم أو ضغط الدم المرتفع أو عدم انتظام ضربات القلب.<br />- ُمضادات الذُهان (المستخدمة لعلاج بعض الاضطرابات العقلية).<br />- الميثوتريكسات (المستخدمة لعلاج التهاب المفاصل الروماتويدي والصدفية وسرطان الدم).<br />- الكاربامازيبين (المستخدم لعلاج نوبات الصرع/ التشنج وبعض أنواع الألم أو الاكتئاب).<br />- الباربيتورات (المستخدمة لعلاج نوبات الصرع/ التشنج وبعض اضطرابات النوم).<br />- السيكلوسبورين والتاكروليموس (المستخدمان لتثبيط الجهاز المناعي عقب إجراء عمليات زرع الأعضاء على سبيل المثال).<br />يمكن تناول سيباتكس مع جرعة منخفضة من حمض الأسيتيل ساليسيليك ( 75مجم أو أقل يوميا). استشر الطبيب قبل تناول هذين<br />الدواءين معا<br />&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية والخصوبة:</strong><br />إذا كنت حاملا أو في فترة الإرضاع أو تعتقدين أن ِك حامل أو تخططين لذلك، فاستشري الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p>الحمل<br />يجب ألا تتناول الحوامل أو ال ُمقبلات على الحمل (السيدات اللاتي ي ُحتمل حدوث حمل لديهن لعدم استخدام وسائل منع حمل فعالة<br />خلال فترة العلاج) دواء سيباتكس. في حالة حدوث حمل خلال فترة العلاج بدواء سيباتكس، يجب علي ِك وقف العلاج والاتصال<br />بالطبيب لوصف علاج بديل.</p><p>الرضاعة الطبيعية<br />يجب عدم استعمال دواء سيباتكس خلال فترة الرضاعة</p><p>الخصوبة<br />قد تؤدي مضادات الالتهاب اللاستيرويدية - بما في ذلك سيباتكس - إلى صعوبة أكبر في حدوث الحمل. يجب إخطار الطبيب إذا<br />كنت تخططين لحدوث حمل أو إذا كانت لدي ِك مشاكل تحول دون حدوث الحمل.</p><p><strong>تأثير سيباتكس على القيادة واستخدام اللات</strong><br />يجب عليك معرفة كيفية استجابة جسمك لدواء سيباتكس قبل القيادة أو تشغيل الآلات. إذا كنت تشعر بالدوار أو النعاس بعد تناول<br />سيباتكس فتجنب القيادة أو تشغيل الآلات حتى تزول هذه الأعراض.</p><p><strong>يحتوي سيباتكس على اللاكتوز</strong><br />يحتوي سيباتكس على اللاكتوز (أحد أنواع السكر.) إذا أخبرك الطبيب أنك لا تتحمل بعض أنواع السكر فاستشر الطبيب قبل<br />تناول هذا المستحضر الدوائي.</p><p>يحتوي سيباتكس على الصوديوم<br />يحتوي هذا الدواء على أقل من 1مليمول صوديوم ( 23مجم) لكل كبسولة، وهذا يعني بشكل أساسي &quot;خا ٍل من الصوديوم&quot;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائما على تناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. إذا كنت تعتقد أو<br />تشعر أن تأثير سيباتكس قوي جد ا أو ضعيف جد ا، فتحدث إلى طبيبك أو الصيدلي.<br />سيخبرك الطبيب بالجرعة اللازم تناولها. وحيث إن من المحتمل أن يزيد خطر ظهور الآثار الجانبية المرتبطة بمشاكل القلب مع<br />زيادة الجرعة وطول مدة الاستعمال، من المهم استخدام أقل جرعة ممكنة لتسكين الألم، كما يجب عدم تناول سيباتكس لمدة أطول<br />من اللازم للتغلب على الأعراض</p><p><strong>طريقة الاستعمال:</strong><br />سيباتكس كبسولات للاستخدام عن طريق الفم. يمكن تناول الكبسولات في أي وقت خلال اليوم، مع الطعام أو دونه. وبالرغم من<br />ذلك، حاول أن تتناول كل جرعة من سيباتكس في نفس الوقت كل يوم.<br />إذا واجهت صعوبة في ابتلاع الكبسولات: يمكن تفريغ محتويات الكبسولة على معلقة من طعام نصف صلب بارد أو في درجة<br />حرارة الغرفة مثل (صلصة التفاح، عصيدة الأرز، الزبادي أو الموز المهروس) ويتم ابتلاعها فورا مع 240مللي من الماء.<br />لفتح الكبسولة احملها في وضع مستقيم حتى تتجمع الحبيبات في الأسفل ثم أضغط على قمة الكبسولة برفق وأدرها لتزيلها، مع<br />الحرص على عدم تسريب المحتويات. لا تمضغ أو تكسر الحبيبات.<br />اتصل بطبيبك خلال أسبوعين من بداية العلاج إذا لم تشعر بأي تحسن.</p><p><strong>الجرعات المقترحة:</strong><br />لعلاج التهاب المفاصل العظمي، تكون الجرعة المقترحة 200مجم يوميا، ويمكن عند اللزوم أن يزيد الطبيب الجرعة إلى 400<br />مجم بحد أقصى.<br />عادة ما تكون الجرعة:<br />-كبسولة واحدة 200مجم مرة واحدة يوميا أو<br />-كبسولة واحدة 100مجم مرتين يوميا.<br />لعلاج التهاب المفاصل الروماتويدي، تكون الجرعة المقترحة 200مجم يوميا، ويمكن عند اللزوم أن يزيد الطبيب الجرعة إلى<br />400مجم بحد أقصى.<br />عادة ما تكون الجرعة:<br />-كبسولة واحدة 100مجم مرتين يوميا.ً<br />لعلاج التهاب الفقار المتصلب، تكون الجرعة المقترحة 200مجم يوميا ، ويمكن عند اللزوم أن يزيد الطبيب الجرعة إلى 400<br />مجم بحد أقصى.</p><p>عادة ما تكون الجرعة:<br />-كبسولة واحدة 200مجم مرة واحدة يوميا أو<br />-كبسولة واحدة 100مجم مرتين يوميا</p><p>مشاكل الكلى أو الكبد: تأكد من إبلاغ الطبيب إذا كنت تعاني من مشاكل في الكبد أو الكلى فقد تحتاج إلى جرعة أقل.<br />كبار السن، وخاصة ًمن يقل وزنهم عن 50كجم: إذا كان عمرك يزيد عن 65عاما وكان وزنك يقل عن 50كجم، فقد يرغب<br />الطبيب في متابعة حالتك بصفة دورية.</p><p>يجب ألا تتناول أكثر من 400مجم من الدواء يوميا ً</p><p><strong>الاستعمال من قبل الأطفال:</strong><br />دواء سيباتكس للبالغين فقط، وغير مخصص للاستعمال من قبل الأطفال.</p><p><strong>إذا تناولت جرعة زائدة من سيباتكس:</strong><br />يجب عدم تناول كبسولات أكثر مما وصفه الطبيب. إذا تناولت عدد ا زائد من الكبسولات، فاتصل بالطبيب أو الصيدلي أو<br />المستشفى وخذ الدواء معك.</p><p><strong>إذا نسيت تناول سيباتكس:</strong><br />إذا نسيت تناول كبسولة، فتناولها بمجرد أن تتذكر. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p><strong>إذا توقفت عن تناول سيباتكس:</strong><br />قد يؤدي التوقف المفاجئ عن العلاج بدواء سيباتكس إلى ازدياد حدة الأعراض. لا تتوقف عن تناول سيباتكس حتى يخبرك<br />الطبيب بذلك. قد يخبرك الطبيب بتقليل الجرعة على مدار بضعة أيام قبل التوقف عن العلاج نهائيا</p><p>إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>لوحظ ظهور الآثار الجانبية الواردة أدناه لدى المرضى المصابين بالتهاب المفاصل ممن يتلقون العلاج بعقار سيباتكس.<br />وسُجل حدوث الآثار الجانبية التي تحمل علامة النجمة (*) الواردة أدناه بشكل متكرر لدى المرضى الذين يتناولون سيباتكس<br />للوقاية من الأورام الحميدة بالقولون. المرضى في هذه الدراسات تناولوا عقار سيباتكس بجرعات مرتفعة لمدة طويلة.</p><p>إذا حدث أي مما يلي، فتوقف عن تناول سيباتكس وأخبر الطبيب على الفور: إذا أصبت بما يلي:<br />- أحد تفاعلات الحساسية مثل الطفح الجلدي أو تورم الوجه أو الصفير أثناء التنفس أو صعوبة التنفس.<br />- مشاكل في القلب مثل ألم في الصدر.<br />- ألم شديد في المعدة أو ظهور أي علامة على حدوث نزيف في المعدة أو الأمعاء، مثل أن يكون البراز أسود اللون أو مختلطا بالدم<br />أو تقيؤ الدم.<br />- أحد التفاعلات بالجلد مثل الطفح الجلدي أو التقيح أو تقشر الجلد.<br />- فشل الكبد (وتشتمل الأعراض على الغثيان &quot;الشعور بالإعياء&quot;، الإسهال، اليرقان &quot;اصفرار الجلد أو العينين&quot;).<br />آثار جانبية شائعة جد اً: قد تؤثر في أكثر من شخص واحد من كل 10أشخاص<br />ارتفاع ضغط الدم، ويشمل ازدياد سوء حالة ضغط الدم المرتفع الموجود بالفعل*</p><p><strong>آثار جانبية شائعة: قد تؤثر في شخص واحد من كل 10أشخاص</strong><br />- السكتة القلبية*<br />- تراكم السوائل بالجسم مع تورم الكاحلين والساقين و/أو اليدين.<br />- عدوى الجهاز البولي.<br />- ضيق التنفس،* التهاب الجيوب الأنفية (التهاب أو عدوى أو انسداد الجيوب الأنفية أو الشعور بألم فيها،) انسداد الأنف أو الرشح،<br />التهاب الحلق، السعال، نوبات البرد، أعراض شبيهة بالإنفلونزا.<br />- الدوار وصعوبة النوم.<br />- القيء،* ألم المعدة، الإسهال، عسر هضم، غازات.<br />- طفح جلدي، حكة.<br />- تيبس العضلات.<br />- صعوبة البلع*.<br />- الصداع.<br />- الغثيان (الشعور بالإعياء).<br />- ألم في المفاصل.<br />- ازدياد الحساسية الموجودة بالفعل.<br />- الإصابة العارضة</p><p><strong>آثار جانبية غير شائعة: قد تؤثر في شخص واحد من كل 100شخص</strong><br />- السكتة الدماغية*<br />- فشل القلب، خفقان القلب (الشعور بضربات القلب،) سرعة معدل النبض.<br />- تغير نتائج فحوص الدم المتعلقة بالكبد.<br />- تغير نتائج فحوص الدم المتعلقة بالكلى.<br />- فقر الدم (تغيرات في كرات الدم الحمراء تؤدي إلى الشعور بالتعب وضيق التنفس).<br />القلق، الاكتئاب، الشعور بالتعب، النعاس، الشعور بالنخز (كوخز الدبابيس والإبر).<br />- ارتفاع مستويات البوتاسيوم في نتائج فحوص الدم (قد يسبب الغثيان (الشعور بالإعياء،) أو التعب، أو ضعف العضلات أو خفقان<br />القلب.)<br />- ضعف الرؤية أو عدم وضوح الرؤية، طنين في الأذنين، ألم وتقرحات في الفم، صعوبة السمع*<br />- الإمساك، التجشؤ، التهاب المعدة (عسر هضم أو ألم في المعدة أو قيء،) ازدياد سوء حالة التهاب المعدة أو الأمعاء.<br />- تشنجات في عضلات الساق.<br />- زيادة الطفح الجلدي المصحوب بحكة (الشرى).<br />- التهاب العينين.<br />- صعوبة التنفس.<br />- تغير لون الجلد (كدمات).<br />- ألم في الصدر (ألم عام غير مرتبط بالقلب).<br />- تورم الوجه</p><p><strong>آثار جانبية نادرة: قد تؤثر في شخص واحد من كل 1,000شخص</strong><br />- قرحة (نزيف) في المعدة، أو المريء أو الأمعاء؛ أو تمزق في الأمعاء (قد يسبب آلام في المعدة، حمى، قيء، انسداد في<br />الأمعاء،) براز داكن أو أسود اللون، التهاب البنكرياس (قد يؤدي إلى ألم في المعدة،) التهاب المريء.<br />- انخفاض مستويات الصوديوم في الدم (حالة مرضية تعُرف باسم نقص صوديوم الدم).<br />- نقص عدد كرات الدم البيضاء (التي تساعد في حماية الجسم من الإصابة بالعدوى) أو الصفائح الدموية (زيادة فرصة الإصابة<br />بالنزيف او الكدمات)<br />- صعوبة التنسيق بين الحركات العضلية.<br />- الشعور بالارتباك، وتغير مذاق الطعام.<br />- الحساسية الزائدة للضوء.<br />- تساقط الشعر.<br />- الهلوسة.<br />- نزيف العين.<br />- رد فعل حاد قد يؤدي إلى التهاب الرئة<br />- عدم انتظام ضربات القلب.<br />- احمرار<br />- تجلط الدم في الأوعية الدموية بالرئتين. قد تتضمن الأعراض حدوث ضيق تنفس مفاجئ أو آلام حادة عند التنفس أو انكماش<br />الرئة.<br />- نزيف المعدة أو الأمعاء (مما قد يؤدي إلى البراز أو القيء المختلط بالدم،) التهاب الأمعاء أو القولون.<br />- التهاب الكبد الشديد (الالتهاب الكبدي.) قد تشتمل الأعراض على الغثيان (الشعور بالإعياء،) الإسهال، اليرقان (تغير لون الجلد أو<br />العينين إلى اللون الأصفر،) البول الداكن، البراز الباهت اللون، سرعة النزف، الحكة، القشعريرة.<br />- الفشل الكلوي الحاد.<br />- اضطرابات الدورة الشهرية.<br />- تورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق أو صعوبة البلع.</p><p><strong>آثار جانبية نادرة جد اً: قد تؤثر في شخص واحد من كل 10,000شخص</strong><br />- تفاعلات الحساسية الشديدة (وتشمل حدوث صدمة فرط الحساسية التي قد تؤدي الى الوفاة).<br />- الأمراض الجلدية الخطيرة مثل متلازمة ستيفنز جونسون والتهاب الجلد التقشري ومتلازمة انحلال البشرة السمي (قد تسبب<br />طفح جلدي أو تقيح أو تقشر الجلد) وطفح جلدي متقيح حاد وعام (وتشتمل الأعراض على احمرار الجلد مع تورم بعض المناطق<br />وامتلائها بالعديد من البثور الصغيرة.)<br />- تفاعل حساسية متأخر تُصاحبه أعراض محتملة مثل الطفح الجلدي وتورم الوجه والحمى وتورم الغدد واختلال نتائج الفحوص<br />(مثل وظائف الكبد وكرات الدم، (زيادة نوع عدد من كرات الدم البيضاء))<br />- نزيف المخ المسبب للوفاة.<br />- الالتهاب السحائي (التهاب الغشاء المحيط بالمخ والحبل الشوكي).<br />- فشل الكبد وتضرر الكبد والالتهاب الكبدي الشديد (التهاب الكبد المفاجئ) (وأحيانا يكون مميتا أو يتطلب عملية زرع كبد.) قد<br />تشتمل الأعراض على الغثيان (الشعور بالإعياء،) الإسهال، اليرقان (تغير لون الجلد أو العينين إلى اللون الأصفر،) البول الداكن،<br />البراز الباهت اللون، سرعة النزف، الحكة، القشعريرة.<br />- مشاكل في الكبد (مثل الركود الصفراوي والتهاب الكبد الصفراوي، الذي قد يكون مصحوبا ببعض الأعراض مثل تغير لون<br />البراز والشعور بالغثيان واصفرار الجلد أو العينين.)<br />التهاب الكلى وغيرها من مشاكل الكلى (مثل المتلازمة الكلوية ومرض التغير الأدنى، الذي قد يكون مصحوبا ببعض الأعراض<br />مثل احتباس الماء داخل الجسم (وذمة) ورغوة بالبول وشعور بالإجهاد وفقدان الشهية.)<br />- ازدياد سوء نوبات الصرع (احتمال حدوثها بشكل أكثر تكرارا و/أو نوبات أكثر حدة).<br />- انسداد أحد الشرايين أو الأوردة بالعين مما يؤدي إلى فقدان حاسة البصر بشكل جزئي أو تام.<br />- التهاب الأوعية الدموية (مما يسبب حمى، آلام، بقع أرجوانية على الجلد).<br />- نقص عدد خلايا الدم الحمراء والبيضاء والصفائح الدموية (مما يسبب الشعور بالتعب والإصابة بالكدمات بسهولة والنزيف<br />المتكرر من الأنف وزيادة خطر الإصابة بالأمراض المعدية.)<br />- ألم وضعف العضلات.<br />- ضعف حاسة الشم.<br />- فقدان حاسة التذوق<br />آثار جانبية غير معروفة: لا يمكن تقييم عدد مرات حدوثها من البيانات المتاحة.<br />- قلة الخصوبة في الإناث، والتي غالبا تعود لطبيعتها مرة أخرى عند التوقف عن تناول الدواء.</p><p><strong>لوحظ ظهور الثار الجانبية الإضافية التالية في بعض الدراسات السريرية غير المرتبطة بالتهاب المفاصل أو حالات التهاب<br />المفاصل الأخرى، حيث كان يستعمل عقار سيليكوكسيب بجرعات يومية مقدارها 400مجم لمدة 3سنوات:</strong><br />&nbsp;</p><p><strong>آثار جانبية شائعة: قد تؤثر في شخص واحد من كل 10أشخاص</strong><br />- مشاكل القلب: الذبحة الصدرية (ألم في الصدر).<br />- مشاكل المعدة: متلازمة القولون العصبي (وتشمل ألم بالمعدة وإسهال وعسر هضم وخروج غازات).<br />- حصوات الكلى (قد تؤدي إلى الشعور بألم في المعدة أو الظهر، ووجود دم في البول،) صعوبة التبول.<br />- زيادة الوزن.</p><p><strong>آثار جانبية غير شائعة: قد تؤثر في شخص واحد من كل 100شخص</strong><br />- تجلط الدم بالأوردة العميقة (عادة ما تحدث جلطات في الساق، مما قد يسبب الألم أو التورم أو احمرار عضلة الساق الخلفية أو<br />مشاكل في التنفس.)<br />- مشاكل المعدة: التهاب المعدة (قد يسبب تهيج المعدة والأمعاء وإصابتها بالقرح).<br />- كسر في الأطراف السفلية.<br />- عدوى فيروسية بالجلد (هربس،) عدوى الجلد، إكزيما (طفح جلدي مصحوب بالجفاف والحكة،) التهاب رئوي (عدوى بالصدر<br />(احتمال الإصابة بالسعال، الحمى، صعوبة التنفس.))<br />- ذبابة العين تسبب غشاوة البصر أو ضعفه، الدوخة نتيجة لمشاكل في الأذن الداخلية، تقرح اللثة أو التهابها أو نزفها، قرح بالفم.<br />- التبول بكثرة أثناء الليل، النزيف من البواسير/ داء البواسير، زيادة حركة الأمعاء.<br />- كتل دهنية في الجلد أو مناطق أخرى، عقدة كيسية (تورم غير ضار حول المفاصل والأوتار في اليدين أو القدمين،) صعوبة<br />الكلام، نزيف غير طبيعي أو شديد جدا من المهبل، ألم في الثدي.<br />- ارتفاع مستويات البوتاسيوم في نتائج فحوص الدم.</p><p><strong>الإبلاغ عن الثار الجانبية:</strong></p><p>إذا ظهرت لديك أي آثار جانبية، تحدث إلى طبيبك أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p><p><strong>للإبلاغ حول الثار الجانبية التي قد تحدث يرجي التواصل عبر العناوين التالية:<br />&bull; المملكة العربية السعودية:</strong></p><p>-المركز الوطني للتيقظ الدوائي:</p><p>رقم الاتصال الموحد: 19999<br />npc.drug@sfda.gov.sa.:البريد الإلكتروني<br />https://ade.sfda.gov.sa :الموقع الإلكتروني</p><p><strong>&bull; الإمارات العربية المتحدة:</strong></p><p>قسم التيقظ الدوائي والأجهزة الطبية<br />صندوق بريد: 1853<br />80011111 :هاتف<br />بريد إلكتروني: pv@mohap.gov.ae<br />إدارة الدواء وزارة الصحة ووقاية المجتمع<br />دبي، الإمارات العربية المتحدة</p><p><strong>&bull; دول الخليج العربي الأخرى:</strong></p><p>الرجاء الاتصال بالجهات الوطنية في كل دولة</p><p><br /><strong>مجلس وزراء الصحة العرب:</strong></p><table><tbody><tr><td>إن هذا الدواء<br />- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافا للتعليمات يعرضك للخطر.<br />- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.<br />- الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.<br />- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.<br />- لا تكرر صرف الدواء بدون استشارة الطبيب المختص.<br />- لا تترك الأدوية في متناول الأطفال.</td></tr></tbody></table><p>مجلس وزراء الصحة العرب<br />واتحاد الصيادلة العرب<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيد عن رؤية ومتناول الأطفال.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العلبة بعد كلمة &quot;.&quot;EXP<br />يحفظ في درجة حرارة لا تزيد عن 30درجة مئوية.<br />يُستخدم خلال 3أشهر من فتح العبوة للمرة الأولي<br />لا تتخلص من الدواء عن طريق رميه في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن<br />كيفية التخلص من الدواء إذا لم تعد بحاجته. هذه الإجراءات تساعد في حماية البيئة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات سيباتكس<br />المادة الفعالة هي سيليكوكسيب. تحتوي كل كبسولة جيلاتينة صلبة على 200مجم سيليكوكسيب.<br />المكونات الأخرى هي لاكتوز أحادي الهيدرات، لوريل سلفات الصوديوم، بوفيدون ، كروسكارميلوز الصوديوم ، ستيرات المغنيسيوم<br />وغلاف الكبسولة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>سيباتكس عبارة عن كبسولات جيلاتينية صلبة ذات غطاء أصفر وجسم أبيض يحتوي على مسحوق حبيبي أبيض إلى أبيض مائل<br />للصفرة.<br />تتوفر كبسولات سيباتكس في عبوة بحجم 30كبسولة جيلاتينة صلبة<br />يتوفر سيباتكس في قنينة بيضاء غير شفافة من البولي إيثيلين عالي الكثافة تحتوي على 30وحدة من كبسولات سيباتكس 200مجم ،<br />ومعبأة في علبة كرتون مع نشرة معلومات للمريض<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع البترجي للأدوية (بترجي فارما)<br />المملكة العربية السعودية، جدة، المنطقة الصناعية، المرحلة الرابعة،<br />قطعة E<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cebatix 200 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 200 mg celecoxib.
Excipient with known effect
Lactose (each capsule contains 49.75 mg lactose monohydrate; see section 4.4).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules (capsule).
Yellow cap and white body, opaque hard gelatin capsule size #2
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cebatix is indicated in adults for the symptomatic relief in the treatment of osteoarthritis, rheumatoid<br />arthritis and ankylosing spondylitis.<br />The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an<br />assessment of the individual patient&#39;s overall risks (see sections 4.3 and 4.4)<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />As the cardiovascular (CV) risks of celecoxib may increase with dose and duration of exposure, the<br />shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for<br />symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients<br />with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).</p><p>Osteoarthritis<br />The usual recommended daily dose is 200 mg taken once daily or in two divided doses. In some<br />patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase<br />efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options<br />should be considered.</p><p>Rheumatoid arthritis<br />The initial recommended daily dose is 200 mg taken in two divided doses. The dose may, if needed,<br />later be increased to 200 mg twice daily. In the absence of an increase in therapeutic benefit after two<br />weeks, other therapeutic options should be considered.</p><p>Ankylosing spondylitis<br />The recommended daily dose is 200 mg taken once daily or in two divided doses. In a few patients,<br />with insufficient relief from symptoms, an increased dose of 400 mg once daily or in two divided<br />doses may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other<br />therapeutic options should be considered.<br />The maximum recommended daily dose is 400 mg for all indications.</p><p><u>Special populations</u><br />Elderly<br />As in younger adults, 200 mg per day should be used initially. The dose may, if needed, later be<br />increased to 200 mg twice daily. Particular caution should be exercised in elderly with a body weight<br />less than 50 kg (see sections 4.4 and 5.2).</p><p>Paediatric population<br />Celecoxib is not indicated for use in children.<br />CYP2C9 poor metabolisers<br />Patients who are known, or suspected to be CYP2C9 poor metabolisers based on genotyping or<br />previous history/experience with other CYP2C9 substrates should be administered celecoxib with<br />caution as the risk of dose-dependent adverse effects is increased. Consider reducing the dose to half<br />the lowest recommended dose (see section 5.2).</p><p>Hepatic impairment<br />Treatment should be initiated at half the recommended dose in patients with established moderate liver<br />impairment with a serum albumin of 25-35 g/l. Experience in such patients is limited to cirrhotic<br />patients (see sections 4.3, 4.4 and 5.2).</p><p>Renal impairment<br />Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore<br />such patients should be treated with caution (see sections 4.3, 4.4 and 5.2).</p><p><u>Method of administration</u><br />Oral use</p><p>Cebatix may be taken with or without food. For patients who have difficulty swallowing capsules, the<br />contents of a celecoxib capsule can be added to applesauce, rice gruel, yogurt or mashed banana. To<br />do so, the entire capsule contents must be carefully emptied onto a level teaspoon of cool or room<br />temperature applesauce, rice gruel, yogurt or mashed banana and should be ingested immediately with<br />240 ml of water. The sprinkled capsule contents on applesauce, rice gruel or yogurt are stable for up to<br />6 hours under refrigerated conditions (2-8 &deg;C). The sprinkled capsule contents on mashed banana<br />should not be stored under refrigerated conditions and should be ingested immediately.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Known hypersensitivity to sulfonamides.
Active peptic ulceration or gastrointestinal (GI) bleeding.
Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or
other allergic-type reactions after taking acetylsalicylic acid (aspirin) or other non-steroidal antiinflammatory drugs (NSAIDs) including COX-2 inhibitors.
In pregnancy and in women of childbearing potential unless using an effective method of
contraception (see section 4.6). Celecoxib has been shown to cause malformations in the two animal
species studied (see sections 4.6 and 5.3). The potential for human risk in pregnancy is unknown, but
cannot be excluded.
Breast-feeding (see sections 4.6 and 5.3).
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
Patients with estimated creatinine clearance <30 ml/min.
Inflammatory bowel disease.
Congestive heart failure (NYHA II-IV).Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastrointestinal (GI) effects</u><br />Upper and lower gastrointestinal complications (perforations, ulcers or bleedings [PUBs]), some of<br />them resulting in fatal outcome, have occurred in patients treated with celecoxib. Caution is advised<br />with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the<br />elderly, patients using any other NSAID or antiplatelet drugs (such as acetylsalicylic acid), or<br />glucocorticoids concomitantly, patients using alcohol, or patients with a prior history of<br />gastrointestinal disease, such as ulceration and GI bleeding.<br />There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal<br />ulceration or other gastrointestinal complications), when celecoxib is taken concomitantly with<br />acetylsalicylic acid (even at low doses). A significant difference in GI safety between selective COX-2<br />inhibitors + acetylsalicylic acid vs. NSAIDs + acetylsalicylic acid has not been demonstrated in longterm clinical trials (see section 5.1).</p><p><u>Concomitant NSAID use</u><br />The concomitant use of celecoxib and a non-aspirin NSAID should be avoided.</p><p><u>Cardiovascular effects</u><br />Increased number of serious cardiovascular (CV) events, mainly myocardial infarction, has been found<br />in a long-term placebo-controlled study in subjects with sporadic adenomatous polyps treated with<br />celecoxib at doses of 200 mg bis in die (BID) and 400 mg BID compared to placebo (see section 5.1).<br />As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest<br />duration possible and the lowest effective daily dose should be used. NSAIDs, including COX-2<br />selective inhibitors, have been associated with increased risk of cardiovascular and thrombotic adverse<br />events when taken long-term. The exact magnitude of the risk associated with a single-dose has not<br />been determined, nor has the exact duration of therapy associated with increased risk. The patient&#39;s<br />need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in<br />patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).<br />Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia,<br />diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see<br />section 5.1).</p><p>COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of<br />cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects. Therefore,<br />antiplatelet therapies should not be discontinued (see section 5.1).</p><p><u>Fluid retention and oedema</u><br />As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention and oedema<br />have been observed in patients taking celecoxib. Therefore, celecoxib should be used with caution in<br />patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients<br />with pre-existing oedema from any other reason, since prostaglandin inhibition may result in<br />deterioration of renal function and fluid retention. Caution is also required in patients taking diuretic<br />treatment or otherwise at risk of hypovolaemia.</p><p><u>Hypertension</u><br />As with all NSAIDS, celecoxib can lead to the onset of new hypertension or worsening of pre-existing<br />hypertension, either of which may contribute to the increased incidence of cardiovascular events.<br />Therefore, blood pressure should be monitored closely during the initiation of therapy with celecoxib<br />and throughout the course of therapy.</p><p><u>Hepatic and renal effects</u><br />Compromised renal or hepatic function and especially cardiac dysfunction are more likely in the<br />elderly and therefore medically appropriate supervision should be maintained.<br />NSAIDs, including celecoxib, may cause renal toxicity. Clinical trials with celecoxib have shown<br />renal effects similar to those observed with comparator NSAIDs. Patients at greatest risk for renal<br />toxicity are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics,<br />angiotensin converting enzyme (ACE)-inhibitors, angiotensin II receptor antagonists, and the elderly<br />(see section 4.5). Such patients should be carefully monitored while receiving treatment with<br />celecoxib.</p><p>Some cases of severe hepatic reactions, including fulminant hepatitis (some with fatal outcome), liver<br />necrosis and, hepatic failure (some with fatal outcome or requiring liver transplant), have been<br />reported with celecoxib. Among the cases that reported time to onset, most of the severe adverse<br />hepatic events developed within one month after initiation of celecoxib treatment (see section 4.8).<br />If during treatment, patients deteriorate in any of the organ system functions described above,<br />appropriate measures should be taken and discontinuation of celecoxib therapy should be considered.</p><p><u>CYP2D6 inhibition</u><br />Celecoxib inhibits CYP2D6. Although it is not a strong inhibitor of this enzyme, a dose reduction may<br />be necessary for individually dose-titrated medicinal products that are metabolised by CYP2D6 (see<br />section 4.5).</p><p><u>CYP2C9 poor metabolisers</u><br />Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).</p><p><u>Skin and systemic hypersensitivity reactions</u><br />Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson<br />syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use<br />of celecoxib (see section 4.8). Patients appear to be at highest risk for these reactions early in the<br />course of therapy: the onset of the reaction occurring in the majority of cases within the first month of<br />treatment. Serious hypersensitivity reactions (including anaphylaxis, angioedema and drug rash with<br />eosinophilia and systemic symptoms (DRESS), or hypersensitivity syndrome), have been reported in<br />patients receiving celecoxib (see section 4.8). Patients with a history of sulfonamide allergy or any<br />drug allergy may be at greater risk of serious skin reactions or hypersensitivity reactions (see section<br />4.3). Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any<br />other sign of hypersensitivity.</p><p><u>General</u><br />Celecoxib may mask fever and other signs of inflammation.</p><p><u>Use with oral anticoagulants</u><br />In patients on concurrent therapy with warfarin, serious bleeding events, some of them fatal, have been<br />reported. Increased prothrombin time (INR) with concurrent therapy has been reported. Therefore, this<br />should be closely monitored in patients receiving warfarin/coumarin-type oral anticoagulants,<br />particularly when therapy with celecoxib is initiated or celecoxib dose is changed (see section 4.5).<br />Concomitant use of anticoagulants with NSAIDS may increase the risk of bleeding. Caution should be<br />exercised when combining celecoxib with warfarin or other oral anticoagulants, including novel<br />anticoagulants (e.g. apixaban, dabigatran, and rivaroxaban).</p><p><u>Excipients</u><br />Cebatix 200 mg capsules contain lactose (49.75 mg, respectively). Patients with rare hereditary<br />problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should<br />not take this medicine.</p><p>Cebatix 200 mg contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially<br />&#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u><br />Anticoagulants<br />Anticoagulant activity should be monitored particularly in the first few days after initiating or<br />changing the dose of celecoxib in patients receiving warfarin or other anticoagulants since these<br />patients have an increased risk of bleeding complications. Therefore, patients receiving oral<br />anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first<br />few days when therapy with celecoxib is initiated or the dose of celecoxib is changed (see section 4.4).<br />Bleeding events in association with increases in prothrombin time have been reported, predominantly<br />in the elderly, in patients receiving celecoxib concurrently with warfarin, some of them fatal.</p><p>Anti-hypertensives<br />NSAIDs may reduce the effect of anti-hypertensive medicinal products including ACE-inhibitors,<br />angiotensin II receptor antagonists, diuretics and beta-blockers. As for NSAIDs, the risk of acute renal<br />insufficiency, which is usually reversible, may be increased in some patients with compromised renal<br />function (e.g. dehydrated patients, patients on diuretics, or elderly patients) when ACE-inhibitors,<br />angiotensin II receptor antagonists, and/or diuretics are combined with NSAIDs, including celecoxib<br />(see section 4.4). Therefore, the combination should be administered with caution, especially in the<br />elderly. Patients should be adequately hydrated and consideration should be given to monitoring of<br />renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>In a 28-day clinical study in patients with lisinopril-controlled Stage I and II hypertension,<br />administration of celecoxib 200 mg BID resulted in no clinically significant increases, when compared<br />to placebo treatment, in mean daily systolic or diastolic blood pressure as determined using 24-hour<br />ambulatory blood pressure monitoring. Among patients treated with celecoxib 200 mg BID, 48 %<br />were considered unresponsive to lisinopril at the final clinic visit (defined as either cuff diastolic blood<br />pressure &gt;90 mmHg or cuff diastolic blood pressure increased &gt;10 % compared to baseline),<br />compared to 27 % of patients treated with placebo; this difference was statistically significant.</p><p>Ciclosporin and tacrolimus<br />Co-administration of NSAIDs and ciclosporin or tacrolimus may increase the nephrotoxic effect of<br />ciclosporin or tacrolimus, respectively. Renal function should be monitored when celecoxib and any of<br />these medicinal products are combined.</p><p>Acetylsalicylic acid<br />Celecoxib can be used with low-dose acetylsalicylic acid but is not a substitute for acetylsalicylic acid<br />for CV prophylaxis. In the submitted studies, as with other NSAIDs, an increased risk of<br />gastrointestinal ulceration or other gastrointestinal complications compared to use of celecoxib alone<br />was shown for concomitant administration of low-dose acetylsalicylic acid (see section 5.1).</p><p><u>Pharmacokinetic interactions</u><br />Effects of celecoxib on other medicinal products</p><p><u>CYP2D6 inhibition</u><br />Celecoxib is an inhibitor of CYP2D6. The plasma concentrations of medicinal products that are<br />substrates of this enzyme may be increased when celecoxib is used concomitantly. Examples of<br />medicinal products which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs),<br />neuroleptics, anti-arrhythmic medicinal products, etc. The dose of individually dose-titrated CYP2D6<br />substrates may need to be reduced when treatment with celecoxib is initiated or increased if treatment<br />with celecoxib is terminated.</p><p>Concomitant administration of celecoxib 200 mg twice daily resulted in 2.6-fold and 1.5-fold<br />increases in plasma concentrations of dextromethorphan and metoprolol (CYP2D6 substrates),<br />respectively. These increases are due to celecoxib inhibition of the CYP2D6 substrate metabolism.</p><p><u>CYP2C19 inhibition</u><br />In vitro studies have shown some potential for celecoxib to inhibit CYP2C19 catalysed metabolism.<br />The clinical significance of this in vitro finding is unknown. Examples of medicinal products which<br />are metabolised by CYP2C19 are diazepam, citalopram and imipramine.</p><p><u>Methotrexate</u><br />In patients with rheumatoid arthritis celecoxib had no statistically significant effect on the<br />pharmacokinetics (plasma or renal clearance) of methotrexate (in rheumatologic doses). However,<br />adequate monitoring for methotrexate-related toxicity should be considered when combining these two<br />medicinal products.<br />&nbsp;</p><p><u>Lithium</u><br />In healthy subjects, co-administration of celecoxib 200 mg twice daily with 450 mg twice daily of<br />lithium resulted in a mean increase in Cmax of 16 % and in area under the curve (AUC) of 18 % of<br />lithium. Therefore, patients on lithium treatment should be closely monitored when celecoxib is<br />introduced or withdrawn.</p><p><u>Oral contraceptives</u><br />In an interaction study, celecoxib had no clinically relevant effects on the pharmacokinetics of oral<br />contraceptives (1 mg norethisterone /35 micrograms ethinylestradiol).<br />Glibenclamide/tolbutamide<br />Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide<br />to a clinically relevant extent.<br />Effects of other medicinal products on celecoxib</p><p>CYP2C9 poor metabolisers<br />In individuals who are CYP2C9 poor metabolisers and demonstrate increased systemic exposure to<br />celecoxib, concomitant treatment with CYP2C9 inhibitors such as fluconazole could result in further<br />increases in celecoxib exposure. Such combinations should be avoided in known CYP2C9 poor<br />metabolisers (see sections 4.2 and 5.2).</p><p>CYP2C9 inhibitors and inducers<br />Since celecoxib is predominantly metabolised by CYP2C9 it should be used at half the recommended<br />dose in patients receiving fluconazole. Concomitant use of 200 mg single-dose of celecoxib and 200<br />mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib<br />Cmax of 60% and in AUC of 130%. Concomitant use of inducers of CYP2C9 such as rifampicin,<br />carbamazepine and barbiturates may reduce plasma concentrations of celecoxib.</p><p>Ketoconazole and antacids<br />Ketoconazole or antacids have not been observed to affect the pharmacokinetics of celecoxib.<br />Paediatric population<br />Interaction studies have only been performed in adults.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see<br />sections 4.3 and 5.3). Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data<br />from epidemiological studies suggest an increased risk of spontaneous abortion after use of<br />prostaglandin synthesis inhibitors in early pregnancy. The potential for human risk in pregnancy is<br />unknown, but cannot be excluded. Celecoxib, as with other medicinal products inhibiting<br />prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus<br />during the last trimester.</p><p>During the second or third trimester of pregnancy, NSAIDs including celecoxib may cause fetal renal<br />dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe<br />cases. Such effects may occur shortly after treatment initiation and are usually reversible upon<br />discontinuation.<br />Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see sections 4.3<br />and 4.4). If a woman becomes pregnant during treatment, celecoxib should be discontinued.</p><p><u>Breast-feeding</u><br />Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma.<br />Administration of celecoxib to a limited number of lactating women has shown a very low transfer of<br />celecoxib into breast milk. Women who take Cebatix should not breastfeed.<br />&nbsp;</p><p><u>Fertility</u><br />Based on the mechanism of action, the use of NSAIDs, including celecoxib, may delay or prevent<br />rupture of ovarian follicles, which has been associated with reversible infertility in some women.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cebatix may have minor influence on the ability to drive and use machines.<br />Patients who experience dizziness, vertigo or somnolence while taking Cebatix should refrain from<br />driving or operating machinery.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed by system organ class and ranked by frequency in Table 1, reflecting data<br />from the following sources:<br />&bull; Adverse reactions reported in osteoarthritis patients and rheumatoid arthritis patients at incidence<br />rates greater than 0.01 % and greater than those reported for placebo during 12 placebo- and/or activecontrolled clinical trials of duration up to 12 weeks at celecoxib daily doses from 100 mg up to 800<br />mg. In additional studies using non-selective NSAID comparators, approximately 7 400 arthritis<br />patients have been treated with celecoxib at daily doses up to 800 mg, including approximately 2 300<br />patients treated for 1 year or longer. The adverse reactions observed with celecoxib in these additional<br />studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in Table 1.<br />&bull; Adverse reactions reported at incidence rates greater than placebo for subjects treated with celecoxib<br />400 mg daily in long-term polyp prevention trials of duration up to 3 years (the Adenoma Prevention<br />with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials;<br />see section 5.1, Cardiovascular safety &ndash; long-term studies involving patients with sporadic<br />adenomatous polyps).</p><p><br />&bull; Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period<br />in which an estimated &gt;70 million patients were treated with celecoxib (various doses, durations, and<br />indications). Even though these were identified as reactions from post-marketing reports, trial data was<br />consulted to estimate frequency. Frequencies are based on a cumulative meta-analysis with pooling of<br />trials representing exposure in 38102 patients.<br />Table 1. Adverse drug reactions in celecoxib clinical trials and surveillance experience<br />(MedDRA preferred terms)1,2</p><table><tbody><tr><td>Adverse Drug Reaction Frequency</td></tr><tr><td>System organ<br />class</td><td>Very common<br />(&ge; 1/10)</td><td>Common<br />(&ge; 1/100 to &lt;<br />1/10)</td><td>Uncommon<br />(&ge; 1/1,000 to &lt;<br />1/100)</td><td>Rare<br />(&ge; 1/10,000 to<br />&lt; 1/1,000)</td><td>Very rare<br />(&lt; 1/10,000)</td><td>Not<br />known<br />(cannot be<br />estimated<br />from<br />available<br />data)</td></tr><tr><td>Infections and<br />infestations</td><td>Sinusitis, upper<br />respiratory tract<br />infection,<br />pharyngitis,<br />urinary tract<br />infection</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>Blood and<br />lymphatic<br />system<br />disorders</td><td>Anaemia</td><td>Leukopenia,<br />thrombo<br />cytopenia</td><td>Pancytopenia4</td></tr><tr><td>Immune system<br />disorders</td><td>Hypersensitivity</td><td>Anaphylactic<br />shock4,<br />anaphylactic<br />reaction4</td></tr><tr><td>Metabolism<br />and nutrition<br />disorders</td><td>Hyperkalaemia</td></tr><tr><td>Psychiatric<br />disorders</td><td>Insomnia</td><td>Anxiety,<br />depression,<br />fatigue</td><td>Confusional<br />state,<br />hallucinations4</td></tr><tr><td>Nervous system<br />disorders</td><td>Dizziness,<br />hypertonia,<br />headache4</td><td>Cerebral<br />infarction1,<br />paraesthesia,<br />somnolence</td><td>Ataxia,<br />dysgeusia</td><td>Haemorrhage<br />intracranial<br />(including fatal<br />intracranial<br />haemorrhage)4,<br />meningitis<br />aseptic4, epilepsy<br />(including<br />aggravated<br />epilepsy)4,<br />ageusia4, anosmia4</td></tr><tr><td>Eye disorders</td><td>Vision blurred,<br />conjunctivitis4</td><td>Eye<br />haemorrhage4</td><td>Retinal artery<br />occlusion4, retinal<br />vein occlusion4</td></tr><tr><td>Ear and<br />labyrinth<br />disorders</td><td>Tinnitus,<br />hypoacusis1</td></tr><tr><td>Cardiac<br />disorders</td><td>Myocardial<br />infarction1</td><td>Cardiac failure,<br />palpitations,<br />tachycardia</td><td>Arrhythmia4</td></tr><tr><td>Vascular<br />disorders</td><td>Hyper<br />tension1 (including<br />aggravated hyper<br />tension)</td><td>Pulmonary<br />embolism4,<br />flushing4</td><td>Vasculitis4</td></tr><tr><td>Respiratory,<br />thoracic, and<br />mediastinal<br />disorders</td><td>Rhinitis, cough,<br />dyspnoea1</td><td>Bronchospasm4</td><td>Pneumonitis4</td></tr><tr><td>Gastrointestinal<br />disorders</td><td>Nausea4,<br />abdominal pain,<br />diarrhoea,<br />dyspepsia,<br />flatulence,<br />vomiting1,<br />dysphagia1</td><td>Constipation,<br />gastritis,<br />stomatitis,<br />gastrointestinal<br />inflammation<br />(including<br />aggravation of<br />gastrointestinal<br />inflammation),<br />eructation</td><td>Gastro<br />intestinal<br />haemorrhage4,<br />duodenal<br />ulcer, gastric<br />ulcer,<br />oesophageal<br />ulcer,<br />intestinal<br />ulcer, large<br />intestinal<br />ulcer,<br />intestinal<br />perforation,</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>oesophagitis,<br />melaena,<br />pancreatitis,<br />colitis4</td></tr><tr><td>Hepatobiliary<br />disorders</td><td>Hepatic<br />function<br />abnormal,<br />hepatic enzyme<br />increased<br />(including<br />increased<br />SGOT and<br />SGPT)</td><td>Hepatitis4</td><td>Hepatic<br />failure4 (sometimes<br />fatal or requiring<br />liver transplant),<br />hepatitis<br />fulminant4 (some<br />with fatal<br />outcome), hepatic<br />necrosis4,<br />cholestasis4,<br />hepatitis<br />cholestatic4,<br />jaundice4</td></tr><tr><td>Skin and<br />subcutaneous<br />tissue disorders</td><td>Rash, pruritus<br />(includes<br />pruritus<br />generalised)</td><td>Urticaria,<br />ecchymosis4</td><td>Angioedema4,<br />alopecia,<br />photo<br />sensitivity</td><td>Dermatitis<br />exfoliative4,<br />erythema<br />multiforme4,<br />Stevens-Johnson<br />syndrome4, toxic<br />epidermal<br />necrolysis4, drug<br />reaction with<br />eosinophilia and<br />systemic<br />symptoms<br />(DRESS) 4, acute<br />generalised<br />exanthematous<br />pustulosis<br />(AGEP)4,<br />dermatitis bullous4</td></tr><tr><td>Musculoskeletal<br />and connective<br />tissue disorders</td><td>Arthralgia4</td><td>Muscle spasms<br />(leg cramps)</td><td>Myositis4</td></tr><tr><td>Renal and<br />urinary<br />disorders</td><td>Blood<br />creatinine<br />increased,<br />blood urea<br />increased</td><td>Renal failure<br />acute4, hypo<br />natraemia4</td><td>Tubulointerstitial<br />nephritis4,<br />nephrotic<br />syndrome4,<br />glomerulonephritis<br />minimal lesion4</td></tr><tr><td>Reproductive<br />system and<br />breast<br />disorders</td><td>Menstrual<br />disorder4</td><td>Infertility<br />female<br />(female<br />fertility<br />decreased)3</td></tr><tr><td>General<br />disorders and<br />administrative<br />site conditions</td><td>Influenza-like<br />illness, oedema<br />peripheral/ fluid<br />retention</td><td>Face oedema,<br />chest pain4</td></tr></tbody></table><p>&nbsp;</p><table><tbody><tr><td>Injury,<br />poisoning and<br />procedural<br />complications</td><td>Injury<br />(accidental<br />injury)</td></tr><tr><td>SGOT - serum glutamic oxaloacetic transaminase<br />SGPT - serum glutamic pyruvic transaminase<br />1 Adverse drug reactions that occurred in polyp prevention trials, representing subjects treated with<br />celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials).<br />The adverse drug reactions listed above for the polyp prevention trials are only those that have been<br />previously recognised in the post-marketing surveillance experience, or have occurred more<br />frequently than in the arthritis trials.<br />2 Furthermore, the following previously unknown adverse reactions occurred in polyp prevention<br />trials, representing subjects treated with celecoxib 400 mg daily in 2 clinical trials of duration up to<br />3 years (the APC and PreSAP trials):<br />Common: angina pectoris, irritable bowel syndrome, nephrolithiasis, blood creatinine increased,<br />benign prostatic hyperplasia, weight increased. Uncommon: helicobacter infection, herpes zoster,<br />erysipelas, bronchopneumonia, labyrinthitis, gingival infection, lipoma, vitreous floaters,<br />conjunctival haemorrhage, deep vein thrombosis, dysphonia, haemorrhoidal haemorrhage, frequent<br />bowel movements, mouth ulceration, allergic dermatitis, ganglion, nocturia, vaginal haemorrhage,<br />breast tenderness, lower limb fracture, blood sodium increased.<br />3 Women intending to become pregnant are excluded from all trials, thus consultation of the trial<br />database for the frequency of this event was not reasonable.<br />4 Frequencies are based on cumulative meta-analysis with pooling of trials representing exposure in<br />38102 patients.</td></tr></tbody></table><p>&nbsp;</p><p>In final data (adjudicated) from the APC and PreSAP trials in patients treated with celecoxib 400 mg<br />daily for up to 3 years (pooled data from both trials; see section 5.1 for results from individual trials),<br />the excess rate over placebo for myocardial infarction was 7.6 events per 1,000 patients (uncommon)<br />and there was no excess rate for stroke (types not differentiated) over placebo.</p><p>To report any side effect(s):<br /><strong>&bull; Saudi Arabia:</strong></p><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/<br /><br /><strong>&bull; United Arab Emirates</strong></p><p>- Pharmacovigilance &amp; Medical Device section<br />- P.O.Box: 1853<br />- Tel: 80011111<br />- Email : pv@mohap.gov.ae<br />- Drug Department Ministry of Health &amp; Prevention Dubai, UAE<br /><br /><strong>&bull; Other GCC states</strong><br />- Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience of overdose. Single-doses up to 1200 mg and multiple doses up to 1200<br />mg twice daily have been administered to healthy subjects for nine days without clinically significant<br />adverse effects. In the event of suspected overdose, appropriate supportive medical care should be<br />provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution<br />of symptomatic treatment. Dialysis is unlikely to be an efficient method of medicinal product removal<br />due to high protein binding<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Non-steroidal anti-inflammatory and antirheumatic drugs, NSAIDs,<br />Coxibs, ATC code: M01AH01.<br />&nbsp;</p><p><u>Mechanism of action</u><br />Celecoxib is an oral, selective, COX-2 inhibitor within the clinical dose range (200-400 mg daily). No<br />statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2]<br />formation) was observed in this dose range in healthy volunteers.<br />&nbsp;</p><p><u>Pharmacodynamic effects</u><br />Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2,<br />have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by proinflammatory stimuli and has been postulated to be primarily responsible for the synthesis of<br />prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation,<br />implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous<br />system functions (fever induction, pain perception and cognitive function). It may also play a role in<br />ulcer healing. COX-2 has been identified in tissue around gastric ulcers in humans but its relevance to<br />ulcer healing has not been established.</p><p>The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective<br />inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2<br />selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin<br />without affecting platelet thromboxane.<br />Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides<br />(e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxizole and other<br />sulfonamide antibiotics).</p><p>A dose-dependent effect on TxB2 formation has been observed after high doses of celecoxib.<br />However, in healthy subjects, in small multiple dose studies with 600 mg BID (three times the highest<br />recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to<br />placebo.</p><p><u>Clinical efficacy and safety</u><br />Several clinical studies have been performed confirming efficacy and safety in osteoarthritis,<br />rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the<br />inflammation and pain of osteoarthritis of the knee and hip in approximately 4200 patients in placebo<br />and active-controlled trials of up to 12 weeks duration. It was also evaluated for treatment of the<br />inflammation and pain of rheumatoid arthritis in approximately 2100 patients in placebo and activecontrolled trials of up to 24 weeks duration. Celecoxib at daily doses of 200 mg &ndash; 400 mg provided<br />pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of<br />ankylosing spondylitis in 896 patients in placebo and active-controlled trials of up to 12 weeks<br />duration. Celecoxib at doses of 100 mg BID, 200 mg QD, 200 mg BID and 400 mg QD in these<br />studies demonstrated significant improvement in pain, global disease activity and function in<br />ankylosing spondylitis.</p><p><br />Five randomised double-blind controlled studies have been conducted including scheduled upper<br />gastrointestinal endoscopy in approximately 4500 patients free from initial ulceration (celecoxib doses<br />from 50 mg &ndash; 400 mg BID). In twelve week endoscopy studies celecoxib (100 &ndash; 800 mg per day) was<br />associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1000 mg<br />per day) and ibuprofen (2400 mg per day). The data were inconsistent in comparison with diclofenac<br />(150 mg per day). In two of the 12-week studies the percentage of patients with endoscopic<br />gastroduodenal ulceration was not significantly different between placebo and celecoxib 200 mg BID<br />and 400 mg BID.</p><p><br />In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study), 5,800<br />osteoarthritis and 2,200 rheumatoid arthritis patients received celecoxib 400 mg BID (4-fold and 2-<br />fold the recommended osteoarthritis and rheumatoid arthritis doses, respectively), ibuprofen 800 mg<br />ter in die (TID) or diclofenac 75 mg BID (both at therapeutic doses). Twenty-two percent of enrolled<br />patients took concomitant low-dose acetylsalicylic acid (&le;325 mg/day), primarily for CV prophylaxis.<br />For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or<br />obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually.<br />Also for the combined NSAID group there was no statistically significant difference for complicated<br />ulcers (relative risk 0.77, 95 % CI 0.41-1.46, based on entire study duration). For the combined<br />endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib<br />group compared to the NSAID group, relative risk 0.66, 95 % CI 0.45-0.97 but not between celecoxib<br />and diclofenac. Those patients on celecoxib and concomitant low-dose acetylsalicylic acid<br />experienced 4-fold higher rates of complicated ulcers as compared to those on celecoxib alone. The<br />incidence of clinically significant decreases in haemoglobin (&gt;2 g/dL), confirmed by repeat testing,<br />was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95<br />% CI 0.17- 0.48. The significantly lower incidence of this event with celecoxib was maintained with<br />or without acetylsalicylic acid use.</p><p><br />In a prospective randomised 24 week safety study in patients who were aged &ge;60 years or had a<br />history of gastroduodenal ulcers [users of acetylsalicylic acid (ASA) excluded], the percentages of<br />patients with decreases in haemoglobin (&ge;2 g/dL) and/or haematocrit (&ge;10 %) of defined or presumed<br />GI origin were lower in patients treated with celecoxib 200 mg twice daily (N=2238) compared to<br />patients treated with diclofenac SR 75 mg twice daily plus omeprazole 20 mg once daily (N=2246)<br />(0.2 % vs. 1.1 % for defined GI origin, p = 0.004; 0.4 % vs. 2.4 % for presumed GI origin, p =<br />0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or<br />haemorrhage were very low with no differences between the treatment groups (4-5 per group).<br />Cardiovascular safety &ndash; long-term studies involving subjects with sporadic adenomatous polyps<br />Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e.,<br />the APC trial and the PreSAP trial. In the APC trial, there was a dose-related increase in the composite<br />endpoint of CV death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to<br />placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant<br />increased risk for the same composite endpoint.</p><p><br />In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of CV<br />death, myocardial infarction, or stroke were 3.4 (95 % CI 1.4 - 8.5) with celecoxib 400 mg twice daily<br />and 2.8 (95 % CI 1.1 - 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite<br />endpoint over 3 years were 3.0 % (20/671 subjects) and 2.5 % (17/685 subjects), respectively,<br />compared to 0.9 % (6/679 subjects) for placebo. The increases for both celecoxib dose groups versus<br />placebo were mainly due to an increased incidence of myocardial infarction.</p><p><br />In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint<br />(adjudicated) was 1.2 (95 % CI 0.6 - 2.4) with celecoxib 400 mg once daily compared to placebo.<br />Cumulative rates for this composite endpoint over 3 years were 2.3 % (21/933 subjects) and 1.9 %<br />(12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was with 1.0 %<br />(9/933 subjects) with celecoxib 400 mg once daily and 0.6 % (4/628 subjects) with placebo.<br />Data from a third long-term study, ADAPT (The Alzheimer&#39;s Disease Anti-inflammatory Prevention<br />Trial), did not show a significantly increased CV risk with celecoxib 200 mg BID compared to<br />placebo. The relative risk compared to placebo for a similar composite endpoint (CV death,<br />myocardial infarction, stroke) was 1.14 (95 % CI 0.61 - 2.15) with celecoxib 200 mg twice daily. The<br />incidence of myocardial infarction was 1.1 % (8/717 patients) with celecoxib 200 mg twice daily and<br />1.2 % (13/1070 patients) with placebo.</p><p><br /><u>Prospective randomised evaluation of celecoxib integrated safety vs. ibuprofen or naproxen<br />(PRECISION)</u><br />The PRECISION study was a double-blind study of cardiovascular safety in Osteo arthritis (OA) or<br />Rheumatoid arthritis (RA) patients with or at high risk for cardiovascular disease comparing<br />Celecoxib (200-400 mg daily) with Naproxen (750-1 000 mg daily) and Ibuprofen (1 800-2 400 mg<br />daily). The primary endpoint, Antiplatelet Trialists Collaboration (APTC), was an independently<br />adjudicated composite of cardiovascular death (including haemorrhagic death), non-fatal myocardial<br />infarction or non-fatal stroke. The study was planned with 80% power to evaluate non-inferiority. All<br />patients were prescribed open-label esomeprazole (20-40 mg) for gastro protection. Patients who were<br />taking low-dose aspirin were permitted to continue therapy, at baseline nearly half of the subjects were<br />on aspirin. Secondary and tertiary endpoints included cardiovascular, gastrointestinal and renal<br />outcomes. The Average Dose dispensed was 209&plusmn;37 mg/day for Celecoxib, 2045&plusmn;246 for Ibuprofen<br />and 852&plusmn;103 for Naproxen.</p><p><br />Regarding the primary endpoint, Celecoxib, as compared with either naproxen or ibuprofen, met all<br />four pre-specified non-inferiority requirements, see Table 2.<br />Other independently adjudicated secondary and tertiary endpoints included cardiovascular,<br />gastrointestinal and renal outcomes. Additionally, there was a 4-month substudy focusing on the<br />effects of the three medicinal products on blood pressure as measured by ambulatory monitoring<br />(ABPM).<br /><strong>Table 2. Primary analysis of the adjudicated APTC composite endpoint</strong></p><table><tbody><tr><td>Intent-To-Treat Analysis (ITT, through month 30)</td></tr><tr><td>Celecoxib 100-200 mg bid</td><td>Ibuprofen 600-800 mg tid</td><td>Naproxen 375-500 mg<br />bid</td></tr><tr><td>N</td><td>8,072</td><td>8,040</td><td>7,969</td></tr><tr><td>Subjects with Events</td><td>188 (2.3%)</td><td>218 (2.7%)</td><td>201 (2.5%)</td></tr><tr><td>Pairwise Comparison</td><td>Celecoxib vs. Naproxen</td><td>Celecoxib vs. Ibuprofen</td><td>Ibuprofen vs. Naproxen</td></tr><tr><td>HR (95% CI)</td><td>0.93 (0.76, 1.13)</td><td>0.86 (0.70, 1.04)</td><td>1.08 (0.89, 1.31)</td></tr><tr><td>Modified Intent-To-Treat Analysis (mITT, on treatment through month 43)</td></tr><tr><td>Celecoxib 100-200 mg bid</td><td>Ibuprofen 600-800 mg tid</td><td>Naproxen 375-500 mg<br />bid</td></tr><tr><td>N</td><td>8,030</td><td>7,990</td><td>7,933</td></tr><tr><td>Subjects with Events</td><td>134 (1.7%)</td><td>155 (1.9%)</td><td>144 (1.8%)</td></tr><tr><td>Pairwise Comparison</td><td>Celecoxib vs. Naproxen</td><td>Celecoxib vs. Ibuprofen</td><td>Ibuprofen vs. Naproxen</td></tr><tr><td>HR (95% CI)</td><td>0.90 (0.72, 1.14)</td><td>0.81 (0.64, 1.02)</td><td>1.12 (0.889, 1.40)</td></tr></tbody></table><p>HR - hazard Ratio<br />BID - bis in die<br />TID - ter in die<br />The results were overall numerically similar in the celecoxib and comparator groups for the secondary<br />and tertiary endpoints and there were overall no unexpected safety findings.<br />Taken together the PRECISION study indicates that celecoxib at the lowest approved dose of 100 mg<br />twice daily is non-inferior to ibuprofen dosed in the range of 600 mg-800 mg three times daily or<br />naproxen dosed in the range of 375 mg-500 mg twice daily with respect to cardiovascular adverse<br />effects. The cardiovascular risks of the NSAID class, including coxibs, are dose-dependent, therefore,<br />the results for celecoxib 200 mg daily on the composite cardiovascular endpoint cannot be<br />extrapolated to dosing regimens using the higher doses of celecoxib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours.<br />Dosing with food (high fat meal) delays absorption of celecoxib by about 1 hour resulting in a Tmax of<br />about 4 hours and increases bioavailability by about 20%.<br />In healthy adult volunteers, the overall systemic exposure (AUC) of celecoxib was equivalent when<br />celecoxib was administered as intact capsule or capsule contents sprinkled on applesauce. There were<br />no significant alterations in Cmax, Tmax or T1/2 after administration of capsule contents on applesauce.<br />&nbsp;</p><p><u>Distribution</u><br />Plasma protein binding is about 97 % at therapeutic plasma concentrations and the medicinal product<br />is not preferentially bound to erythrocytes.<br />Biotransformation<br />Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, inactive as<br />COX-1 or COX-2 inhibitors, have been identified in human plasma i.e., a primary alcohol, the<br />corresponding carboxylic acid and its glucuronide conjugate.<br />Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to<br />reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.<br />In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers,<br />genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median Cmax and AUC0-24 of<br />celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as<br />CYP2C9*3/*3 compared to other genotypes. In three separate single-dose studies, involving a total of<br />5 subjects genotyped as CYP2C9*3/*3, single-dose AUC0-24 increased by approximately 3-fold<br />compared to normal metabolisers. It is estimated that the frequency of the homozygous *3/*3<br />genotype is 0.3-1.0 % among different ethnic groups.<br />Patients who are known, or suspected to be CYP2C9 poor metabolisers based on previous<br />history/experience with other CYP2C9 substrates should be administered celecoxib with caution (see<br />section 4.2).</p><p><br />No clinically significant differences were found in Pharmacokinetic parameters of celecoxib between<br />elderly African-Americans and Caucasians.<br />The plasma concentration of celecoxib is approximately 100 % increased in elderly women (&gt;65<br />years).</p><p><br />Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean<br />increase in Cmax of 53 % and in AUC of 26 % of celecoxib. The corresponding values in patients with<br />moderate hepatic impairment were 41 % and 146 % respectively. The metabolic capacity in patients<br />with mild to moderate impairment was best correlated to their albumin values. Treatment should be<br />initiated at half the recommended dose in patients with moderate liver impairment (with serum<br />albumin 25-35 g/l). Patients with severe hepatic impairment (serum albumin &lt;25 g/l) have not been<br />studied and celecoxib is contraindicated in this patient group.<br />There is little experience of celecoxib in renal impairment. The pharmacokinetics of celecoxib has not<br />been studied in patients with renal impairment but is unlikely to be markedly changed in these<br />patients. Thus caution is advised when treating patients with renal impairment. Severe renal<br />impairment is contraindicated.</p><p><br /><u>Elimination</u><br />Celecoxib is mainly eliminated by metabolism. Less than 1 % of the dose is excreted unchanged in<br />urine. The inter-subject variability in the exposure of celecoxib is about 10-fold. Celecoxib exhibits<br />dose- and time-independent pharmacokinetics in the therapeutic dose range. Elimination half-life is 8-<br />12 hours. Steady state plasma concentrations are reached within 5 days of treatment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical safety data revealed no special hazard for humans based on conventional studies of<br />repeated dose toxicity, mutagenicity or carcinogenicity beyond those addressed in section 4.4, 4.6, and<br />5.1 of the SmPC.</p><p><br />Celecoxib at oral doses &ge;150 mg/kg/day (approximately 2-fold human exposure at 200 mg twice daily<br />as measured by AUC0-24), caused an increased incidence of ventricular septal defects, a rare event, and<br />fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were<br />treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias was observed<br />when rats were given celecoxib at oral doses &ge;30 mg/kg/day (approximately 6-fold human exposure<br />based on the AUC0-24 at 200 mg twice daily) throughout organogenesis. These effects are expected<br />following inhibition of prostaglandin synthesis. In rats, exposure to celecoxib during early embryonic<br />development resulted in pre-implantation and post-implantation losses, and reduced embryo/fetal<br />survival.</p><p><br />Celecoxib was excreted in rat milk. In a peri-post natal study in rats, pup toxicity was observed.<br />In a 2 year toxicity study an increase in nonadrenal thrombosis was observed in male rat at high doses.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsules content</u><br />Lactose monohydrate<br />Sodium lauryl sulphate<br />Povidone K-30<br />Croscarmellose sodium<br />Magnesium stearate<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cebatix Capsules are available in a pack size of 30 hard gelatin capsules<br />Cebatix capsules are provided in a white opaque HDPE bottle containing 30 units of Cebatix 200 mg capsule,<br />packed into a carton box with an insert leaflet.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batterjee Pharmaceutical Factory (BATTERJEE PHARMA)
Plot E2, Phase 4, Industrial City, Jeddah, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>